Press releases
- Press releases
- Browse
Press releases
Cymbalta is the agent most likely to lose patient share to Savella over the next two years, according to a new report from Decision Resources
Patient-flow models will need to take into account that the highest percentage of patients take Lyrica More
Patient-flow models will need to take into account that the highest percentage of patients take Lyrica More
Intas Biopharmaceuticals Limited (IBPL) and European pharmaceutical major Kwizda Pharma GmbH has jointly completed Phase I clinical trial study of NEUKINE®, biosimilar form of recombinant GCSF. More
APR and the leading pharmaceutical company in Turkey Abdi Ibrahim have entered into an exclusive license agreement for the promotion, distribution and marketing of Ondansetron Rapidfilm® in Turkey; terms of the deal were not disclosed. More
However, only 25 percent of mcos will place Provenge on the top tiers of their formularies, according to a new report from Decision Resources More
A flavonoid derived from citrus fruit has shown tremendous promise for preventing weight gain and other signs of metabolic syndrome which can lead to Type 2 Diabetes and increased risk of cardiovascular disease. More
Three-quarters of surveyed MCOs will place Stelara on the same or a more favorable formulary tier as the TNF-alpha inhibitors, according to a new report from Decision Resources More
FDA has approved Cambia™, Potassium Diclofenac Powder for Oral Solution for the treatment of acute migraine attacks with or without aura, originally developed by APR Applied Pharma Research SA (APR) using the patented Dynamic Buffering Technology (DBT). More
Chronic obstructive pulmonary disease (COPD), a respiratory disease commonly known as chronic bronchitis or emphysema, is the fourth leading cause of death worldwide, but a University of Western Ontario researcher is providing new insight into the disease More
At a forum focusing on allergy causes and treatment strategies held in Taipei, botanically-derived health products company Medigreen Biotechnology unveiled its new anti-allergy formulation More
Actemra/Roactemra will emerge as the preferred biological drug for TNF-refractory patients, according to a new report from Decision Resources More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2006 - 8 pages - $1,295
Aug 2010 - 27 pages - $475
Aug 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Sep 2010 - 27 pages - $475
Your selection
- Year
- 2009 del
Browse By
- Industry sector
- Academic/Research
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Non-profit org./Government
- Pharmaceutical
- Research tools
- Service
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us